EGFR and central nervous system cancer: However, in 2021, the WHO introduced updated classification criteria for gliomas, and IDH wild-type astrocytomas with EGFR amplification, chromosome 7 acquisition with chromosome 10 deletion and TERT promoter mutations are also included in glioblastoma if they have any of the molecular phenotypes.